Clonal selection of pre-existing neuroendocrine component in prostate cancer during androgen receptor signaling inhibitor therapy: A case report

Urology Case Reports 2026 Open access

Read full text
Authors: Haruka Kubota, Toshiki Kijima, Hadzki Matsuda, Toshitaka Uematsu, Kohei Takei, Masahiro Yashi, Kazuyuki Ishida, Takao Kamai
DOI: 10.1016/j.eucr.2026.103347
Cited by: 0
References: 17

Abstract

Neuroendocrine prostate cancer (NEPC) is often considered treatment-induced. We report a case with pre-existing neuroendocrine differentiation that became evident during androgen receptor signaling inhibitor (ARSI) therapy. A 79-year-old man with metastatic prostate cancer received degarelix plus apalutamide. Prostate-specific antigen (PSA) decreased to

Fields of Study & Subjects

Prostate Cancer Treatment and Research Prostate Cancer Diagnosis and Treatment Neuroblastoma Research and Treatments

Publication details

Journal / source
Urology Case Reports
Volume
65
Pages
103347–103347
Publication date
14 January 2026
Language
EN